AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer

Datroway, an antibody-drug conjugate (ADC) co-developed by AstraZeneca and Daiichi Sankyo, demonstrated landmark results in a phase 3 trial for patients with triple-negative breast cancer (TNBC) who were ineligible for standard immunotherapy.2346

The trial showed Datroway provided a statistically significant and clinically meaningful improvement in both overall survival and progression-free survival compared to standard chemotherapy.2346

This is the first time a survival benefit has been observed with this class of therapy versus chemotherapy in immunotherapy-ineligible TNBC, a group of patients with very poor prognosis and limited options.23

Datroway targets TROP2, a protein commonly overexpressed in triple-negative and other types of breast cancer.2

Detailed trial data have not yet been released, but results will be presented at an upcoming medical meeting and submitted to global regulators.23

Competing treatments for TNBC in this setting include Gilead's Trodelvy, another TROP2-targeting ADC, though prior studies with Trodelvy have not demonstrated a survival benefit at the current follow-up.2

According to AstraZeneca, approximately 70% of triple-negative breast cancer patients are not eligible for immunotherapy, highlighting the significant need for more effective treatments in this population.2

Sources:

2. https://www.biopharmadive.com/news/astrazeneca-daiichi-datroway-triple-negative-breast-cancer-results/802007/

3. https://www.fiercepharma.com/pharma/az-daiichi-score-landmark-results-adc-datroway-triple-negative-breast-cancer

4. https://firstwordpharma.com/story/6313244

6. https://www.europeanpharmaceuticalreview.com/news/266702/astrazeneca-daiichi-sankyo-datroway-phase-iii-breast-cancer-clinical-trial/